RB1 and cancer: Additional mechanisms contributing to the increased immunogenicity of cancer cells treated with CDK4/6 inhibitors include the Rb-dependent activation of long terminal repeat (LTR) enhancers, which regulate genes involved in immune surveillance and antigen presentation [153].